|
30 Mar 2019 |
StrideBio and Takeda Sign Collaboration and License Agreement to Advance Novel Gene Therapies for Neurological Diseases
|
|
30 Mar 2019 |
CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis
|
|
30 Mar 2019 |
ESSA Pharma Announces Nomination of EPI-7386 as Lead Clinical Candidate in Metastatic Castration-Resistant Prostate Cancer
|
|
30 Mar 2019 |
Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology
|
|
30 Mar 2019 |
Data Safety Monitoring Board Recommends Continuation Of Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
|
|
30 Mar 2019 |
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
|
|
30 Mar 2019 |
Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China
|
|
30 Mar 2019 |
Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team
|
|
30 Mar 2019 |
Velicept Therapeutics Announces Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder (OAB)
|
|
30 Mar 2019 |
Gilead and Galapagos Announce Filgotinib Meets Primary and Key Secondary Endpoints in the Phase 3 FINCH 1 Rheumatoid Arthritis Study
|
|
30 Mar 2019 |
Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients
|
|
30 Mar 2019 |
Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)
|
|
30 Mar 2019 |
Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346
|
|
30 Mar 2019 |
AstraZeneca and Daiichi Sankyo enter collaboration for novel HER2-targeting antibody-drug conjugate
|
|
30 Mar 2019 |
bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype
|
|
30 Mar 2019 |
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics
|
|
30 Mar 2019 |
Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma
|
|
30 Mar 2019 |
Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity
|
|
30 Mar 2019 |
Northern Biologics Reports Initial Phase I Data for MSC-1 at AACR
|
|
30 Mar 2019 |
Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing
|
